June 6, 2017 / 11:17 AM / 2 months ago

BRIEF-Astrazeneca presents Tagrisso trial data

1 Min Read

June 6 (Reuters) - Astrazeneca Plc

* Astrazeneca presents Tagrisso (osimertinib) data in patients with egfr t790m-mutation positive lung cancer and central nervous system metastases

* Tagrisso extended length of time patients with CNS metastases live without disease worsening/death to 11.7 months in AURA3 trial​

* E‍evidence of activity in patients with EGFR mutation-positive NSCLC and leptomeningeal metastases from bloom trial​

* Three patients had AE leading to death, however no deaths were considered possibly causally-related to osimertinib by investigator​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below